PsA treatment at study visit.
| Treatments | VLDA, n = 26 | DAPSA ≤ 4, n = 52^ | cDAPSA ≤ 4, n = 65 |
|---|---|---|---|
| Treatment pattern | |||
| Anti-TNF monotherapy | 11 (42.3) | 14 (29.2) | 17 (26.2) |
| csDMARD and anti-TNF | 6 (23.1) | 14 (29.2) | 19 (29.2) |
| csDMARD monotherapy | 9 (34.6) | 20 (41.7) | 29 (44.6) |
| Anti-TNF-α* | |||
| Etanercept | 8 (47.1) | 12 (42.9) | 16 (44.4) |
| Adalimumab | 8 (47.1) | 12 (42.9) | 15 (41.7) |
| Infliximab | 0 (0.0) | 3 (10.7) | 3 (8.3) |
| Golimumab | 1 (5.9) | 1 (3.6) | 1 (2.8) |
| NSAID** | 9 (34.6) | 19 (39.6) | 28 (43.1) |
| Infiltrations** | 2 (7.7) | 11 (22.9) | 14 (21.5) |
| Corticoids** | 1 (3.8) | 5 (10.4) | 7 (10.8) |
Values are n (%).
↵^ There were 52 patients in DAPSA remission, but complete information was available for only 48.
↵* Monotherapy or combination therapy;
↵** Combination therapy. PsA: psoriatic arthritis; VLDA: very low disease activity; DAPSA: Disease Activity Index for Psoriatic Arthritis; cDAPSA: clinical DAPSA; NSAID: nonsteroidal antiinflammatory drugs; csDMARD: conventional synthetic disease-modifying antirheumatic drugs; TNF: tumor necrosis factor.